Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2023-10-31 Interim / Quarterly Rep…
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapid Dose Therapeutics Corp. Condensed Interim Consolidated Financial Statements August 31, 2023 (Unaudited)' and contains detailed financial statements including statements of financial position, operations, changes in equity, cash flows, and notes. It explicitly states it is an interim report for the three and six months ended August 31, 2023. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of unaudited condensed interim consolidated financial statements prepared under IAS 34 confirms this is a quarterly or interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2023-10-31 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the dosing of the first patient in a Phase 2 clinical trial for a drug candidate (MDNA11) by Medicenna Therapeutics. It provides details about the clinical trial phases, expected future data reporting timelines, and background on the drug and company. There are no financial statements, regulatory filings, or detailed financial results presented. The content focuses on clinical trial progress and future expectations rather than financial or governance information. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and future reporting plans, not a financial report, earnings release, or investor presentation. The document length is 7497 characters, which is sufficient for a detailed announcement but does not contain financial data or formal report content. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2023-10-25 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2023-10-23 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the company's intention to issue common shares to satisfy loan fees and accrued interest on secured convertible notes and secured debt. It details the terms of the financing, the number of shares to be issued, and the pricing basis. There are no financial statements, comprehensive financial data, or detailed analysis of financial results. The document is focused on a financing update related to debt and share issuance as payment. It is not an annual report, earnings release, or management discussion. The content fits the category of Capital/Financing Update (CAP) as it provides information on financing activities and capital structure changes.
2023-10-05 English
Material change report - English.pdf
Regulatory Filings
2023-10-02 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about securities distribution, including issuer details, underwriter information, distribution dates, types of securities distributed, purchaser information, compensation related to the distribution, and details about directors and officers. The form is a regulatory filing related to exempt distributions of securities, which is a compliance and disclosure document rather than a financial report or earnings release. It does not contain financial statements, management discussion, or audit information. The document is a formal regulatory filing required by securities regulators to report exempt distributions. Therefore, it fits best under the category of Regulatory Filings (RNS).
2023-09-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.